Advanced search×

[PARP inhibitors: new therapeutic agents in breast and ovarian cancer].

L Mercier-Vogel, A Bodmer, and M Castiglione

Rev Med Suisse 7(296):1137-40 (2011) PMID 21721203

PARP inhibitors are novel drugs under development in oncology, particularly against breast and ovarian cancer. They act on the DNA repair mechanisms in synergy with the loss of BRCA function of the tumor cells, thereby inducing a genetic instability that leads to cell death. The clinical benefit of PARP inhibitors has been demonstrated for breast and ovarian cancer in BRCA germline mutation carriers. Their use in sporadic triple negative breast cancers, that share similarities with BRCA1 mutated tumors, is currently investigated with encouraging preliminary results.

Version: za2963e q8zaf q8zb5 q8zc3 q8zd8 q8ze4 q8zf0 q8zga

Similar articles you may find interesting…

  1. Infections, immunity and atherosclerosis: Pathogenic mechanisms and unsolved questions
    Daniela Pedicino, Ada Francesca Giglio, and Giovanna Liuzzo

    Int J Cardiol 166(3):572-583 (2013) PMID 22727974

    The role of inflammation and immunity in the pathogenesis and clinical manifestations of atherosclerotic disease has been widely studied. Common infectious diseases can be associated with a chronic inflammatory state which is the hallmark of atherosclerosis, thus suggesting a possibl...
  2. Highly covarying residues have a functional role in antibody constant domains
    Elizabeth A Proctor, Pradeep Kota, and Nikolay V Dokholyan

    Proteins 81(5):884-895 (2013) PMID 23280585

    We identify networks of evolutionarily-related residues in C-class antibody domains by evaluating covariation, a measure of propensity with which residue pairs vary dependently during evolution. We computationally test whether mutation of residues in these networks affects stability of the folded an...
  3. Hydrophobic gentamicin loaded nanoparticles are effective in Brucella melitensis in mice.
    Edurne Imbuluzqueta, Carlos Gamazo, and María J Blanco-Prieto

    Antimicrob Agents Chemother (2013) PMID 23650167

    These results strongly suggest that PLGA nanoparticles containing chemically modified hydrophobic gentamicin may be a promising alternative for the treatment of human brucellosis....